Bardet Biedl Syndrome (BBS)
5 clinical trials · Condition
◉ Watch Bardet Biedl Syndrome (BBS)
| Record | Firm | Date |
|---|---|---|
| Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity (NCT03746522) | Rhythm Pharmaceuticals, Inc. | 2018-11-23 |
| An Expanded Access Protocol for Setmelanotide for Treatment of Bardet-Biedl Syndrome (BBS) (NCT05183802) | Rhythm Pharmaceuticals, Inc. |
Track Bardet Biedl Syndrome (BBS) automatically
Every clearance here is in the API, with alerts when new ones post.